Phuong L Mai1, Helen Q Huang2, Lari B Wenzel3, Paul K Han4, Richard P Moser5, Gustavo C Rodriguez6, John Boggess7, Thomas J Rutherford8, David E Cohn9, Noah D Kauff10, Kelly-Anne Phillips11, Kelly Wilkinson12, Robert M Wenham13, Chad Hamilton14, Matthew A Powell15, Joan L Walker16, Mark H Greene17, Martee L Hensley18. 1. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, 20850-9772, USA. Electronic address: maip@upmc.edu. 2. NRG Oncology, Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, 14263-0001, USA. Electronic address: hhuang@gogstats.org. 3. Center for Health Policy Research, University of California, Irvine, Irvine CA, 92697, USA. Electronic address: lwenzel@uci.edu. 4. Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, 04101, USA. Electronic address: HANP@mmc.org. 5. Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, 20850-9761, USA. Electronic address: moserr@mail.nih.gov. 6. Division of Gynecologic Oncology, North Shore University Health System; Evanston, IL, 60201, USA. Electronic address: grodriguez@northshore.org. 7. Division of Gynecologic Oncology, University of North Carolina at Chapel Hill; Raleigh NY 27607, USA. Electronic address: john_boggess@med.unc.edu. 8. Yale University, Norwalk, CT, 06856, USA. Electronic address: thomas.rutherford@yale.edu. 9. Ohio State University, Columbus Cancer Council; GYN Oncology; Columbus, OH, 43026, USA. Electronic address: david.cohn@osumc.edu. 10. Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center; Surgery Department; New York, NY, 10065, USA. Electronic address: nkauff@northwell.edu. 11. Peter MacCallum Cancer Centre, Division of Cancer Medicine, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 300 AU, Australia. Electronic address: kelly.phillips@petermac.org. 12. University of Mississippi Medical Center, Dept. of Hematology/Oncology, Jackson, MS, 39216, USA. Electronic address: kjeanes@umc.edu. 13. H. Lee Moffitt Cancer Center & Research Institute, Gynecology Oncology Division; Tampa, FL, 33612-9497, USA. Electronic address: robert.wenham@moffitt.org. 14. Walter Reed Army Medical Center, Bethesda, MD, 20889, USA. Electronic address: chad.a.hamilton.mil@health.mil. 15. Washington University School of Medicine, Saint Louis, MO, 63110, USA. Electronic address: mpowell@wustl.edu. 16. Stephenson Cancer Center, Department of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Electronic address: joan-walker@ouhsc.edu. 17. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, 20850-9772, USA. Electronic address: greenem@mail.nih.gov. 18. Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA. Electronic address: hensleym@mskcc.org.
Abstract
BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) and ovarian cancer screening (OCS) are management options for women at increased risk of ovarian cancer. Long-term effects of these interventions on quality of life (QOL) are not well understood. METHODS: GOG-0199 is a prospective cohort study of women at increased ovarian cancer risk who chose either RRSO or OCS as their risk management intervention. At study entry, 6, 12, 24 and 60 months of follow-up, participants completed the QOL questionnaire, which included the Medical Outcome Study Short Form-36, the Impact of Events Scales, the Center for Epidemiological Studies Depression Scale, the State-Trait Anxiety Inventory, the Functional Assessment of Cancer Therapy - Endocrine Subscale, and the Sexual Activity Questionnaire. QOL measures were compared between the RRSO and OCS cohort at baseline and over time. RESULTS: Five-hundred-sixty-two participants in the RRSO cohort and 1,010 in the OCS completed the baseline and at least one follow-up questionnaire. At baseline, participants selecting RRSO reported lower health-related QOL (HRQOL), greater ovarian cancer-related stress, greater anxiety, and more depressive symptomatology, which improved during follow-up, especially for ovarian cancer-related stress. Screening was not found to adversely impact HRQOL. Hormone-related menopausal symptoms worsened and sexual functioning declined during follow-up in both cohorts, but more so among participants who underwent RRSO. CONCLUSIONS: HRQOL improved after surgery among women who chose RRSO and remained stable among participants undergoing screening. The adverse effects of RRSO and screening on short-term and long-term sexual activity and sexual functioning warrant consideration in the decision-making process for high-risk women. Published by Elsevier Inc.
BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) and ovarian cancer screening (OCS) are management options for women at increased risk of ovarian cancer. Long-term effects of these interventions on quality of life (QOL) are not well understood. METHODS:GOG-0199 is a prospective cohort study of women at increased ovarian cancer risk who chose either RRSO or OCS as their risk management intervention. At study entry, 6, 12, 24 and 60 months of follow-up, participants completed the QOL questionnaire, which included the Medical Outcome Study Short Form-36, the Impact of Events Scales, the Center for Epidemiological Studies Depression Scale, the State-Trait Anxiety Inventory, the Functional Assessment of Cancer Therapy - Endocrine Subscale, and the Sexual Activity Questionnaire. QOL measures were compared between the RRSO and OCS cohort at baseline and over time. RESULTS: Five-hundred-sixty-two participants in the RRSO cohort and 1,010 in the OCS completed the baseline and at least one follow-up questionnaire. At baseline, participants selecting RRSO reported lower health-related QOL (HRQOL), greater ovarian cancer-related stress, greater anxiety, and more depressive symptomatology, which improved during follow-up, especially for ovarian cancer-related stress. Screening was not found to adversely impact HRQOL. Hormone-related menopausal symptoms worsened and sexual functioning declined during follow-up in both cohorts, but more so among participants who underwent RRSO. CONCLUSIONS: HRQOL improved after surgery among women who chose RRSO and remained stable among participants undergoing screening. The adverse effects of RRSO and screening on short-term and long-term sexual activity and sexual functioning warrant consideration in the decision-making process for high-risk women. Published by Elsevier Inc.
Authors: Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu Journal: Clin Cancer Res Date: 2017-01-31 Impact factor: 12.531
Authors: Marline G Harmsen; Rosella P M G Hermens; Judith B Prins; Nicoline Hoogerbrugge; Joanne A de Hullu Journal: Crit Rev Oncol Hematol Date: 2015-07-26 Impact factor: 6.312
Authors: John Rensselaer van Nagell; Rachel Ware Miller; Christopher P DeSimone; Frederick R Ueland; Iwona Podzielinski; Scott T Goodrich; Jeff W Elder; Bin Huang; Richard J Kryscio; Edward John Pavlik Journal: Obstet Gynecol Date: 2011-12 Impact factor: 7.661
Authors: Noah D Kauff; Karen E Hurley; Martee L Hensley; Mark E Robson; Gali Lev; Deborah Goldfrank; Mercedes Castiel; Carol L Brown; Jamie S Ostroff; Lucy E Hann; Kenneth Offit; Richard R Barakat Journal: Cancer Date: 2005-07-15 Impact factor: 6.860
Authors: Mark Robson; Martee Hensley; Richard Barakat; Carol Brown; Dennis Chi; Elizabeth Poynor; Kenneth Offit Journal: Gynecol Oncol Date: 2003-05 Impact factor: 5.482
Authors: Mark H Greene; Marion Piedmonte; Dave Alberts; Mitchell Gail; Martee Hensley; Zoe Miner; Phuong L Mai; Jennifer Loud; Gustavo Rodriguez; Jack Basil; John Boggess; Peter E Schwartz; Joseph L Kelley; Katie E Wakeley; Lori Minasian; Stephen Skates Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-03 Impact factor: 4.254